$7m · Seed · Healthtech · Trondheim, Norway
Vitroscope has secured $7m in combined financing to commercialise technology that keeps living human tissue under controlled flow for longer experiments. Cerberus Ventures and YZR Capital co-led a $5m Seed round, while the Research Council of Norway is providing $2m in non-dilutive funding, according to the company announcement.
The $7m headline comprises $5m of equity and $2m of non-dilutive support. Vitroscope says it has raised $8.8m in total to date.
Flow turns a tissue snapshot into a time series
Organoids and fresh human tissue can model disease and treatment responses more directly than simple cell cultures, but static well plates do not reproduce the flow, oxygen and nutrient conditions found in the body. Vitroscope's vitro.alive is a benchtop perfusion system that controls flow, oxygen, pH and temperature while supporting live-cell imaging across six independent experiments. It works with standard inverted microscopes, allowing researchers to keep their existing tissue models.
The commercial value comes from extending both tissue viability and observation time. A longer experiment can show how immune activity or a treatment response develops rather than capturing only an endpoint. That produces longitudinal evidence for drug developers, while the same instrument has to remain simple enough for a laboratory to integrate without rebuilding its imaging workflow.
Higher throughput is the next product test
The funding will support commercial rollout of vitro.alive and validation of vitro.scale, a planned platform for 96 parallel experiments. Customer testing is expected in 2027 ahead of a planned 2028 launch. Vitroscope reports that its current platform maintained vascularised brain organoids under perfusion for seven days and supported organised liver tissue that did not form in standard well plates.
Those studies demonstrate useful biological possibilities, but the scale-up test is reproducibility. Pharmaceutical customers need comparable results across samples, operators and sites before longitudinal tissue data can influence candidate selection. Moving from six experiments to 96 also changes the engineering problem: fluid control, environmental stability and imaging must stay consistent across a much larger array.
Related reading
TechBio x AI Drug Discovery: From Concept to Reality examines why proprietary biological data and wet-lab execution are becoming core infrastructure for drug-discovery platforms.
Sources checked:
Vitroscope funding announcement · Tech.eu reporting · Tech.eu Funding Explorer
